Mohammadi-Fallah Mohammadreza, Hamedanchi Sepehr, Tayyebi-Azar Ali
Urology, Nephrology & Kidney Transplant Research Center, Department of Urology, Imam Medical Center, Urmia University of Medical Sciences, Urmia, Iran.
Korean J Urol. 2012 Jun;53(6):419-23. doi: 10.4111/kju.2012.53.6.419. Epub 2012 Jun 19.
To investigate the prophylactic effect of Tamsulosin, a super-selective alpha-1a adrenergic blocking agent, on the development of urinary retention in men undergoing elective inguinal herniorrhaphy.
From May 2010 through November 2011, a total of 80 males who underwent elective inguinal herniorrhaphy in a university hospital were included in this study. Patients were randomly assigned to one of two groups. In group one (control), the patients were given two doses of placebo orally, 6 hours before surgery and 6 to 12 hours after surgery. Patients in group two were given 0.4 mg of Tamsulosin orally in the same manner as the placebo. All patients were closely followed for 24 hours post-operatively, and any voiding difficulties or urinary retention was recorded.
There were 40 patients in group one (control group) and 40 patients in group two (Tamsulosin group). The patients' mean age was 64 years. In group one, 6 patients and in group two, 1 patient required catheterization. Thus, 15% of patients in group I and 2.5% of patients in group II had urinary retention. The difference in the requirement for catheterization was statistically significant (p=0.04). The technique of herniorrhaphy, the side of the body in which the hernia was located, the type of anesthesia, the duration of the surgery, and the severity of pre-operative urinary symptoms had no significant effect on the incidence of urinary retention.
The use of perioperative Tamsulosin represents an effective strategy to reduce the risk of post-operative urinary retention following inguinal herniorrhaphy.
探讨超选择性α-1a肾上腺素能阻滞剂坦索罗辛对择期腹股沟疝修补术男性患者尿潴留发生的预防作用。
2010年5月至2011年11月，一所大学医院中80例行择期腹股沟疝修补术的男性患者纳入本研究。患者被随机分为两组。第一组（对照组）患者在手术前6小时及手术后6至12小时口服两剂安慰剂。第二组患者以与安慰剂相同的方式口服0.4毫克坦索罗辛。所有患者术后密切随访24小时，记录任何排尿困难或尿潴留情况。
第一组（对照组）有40例患者，第二组（坦索罗辛组）有40例患者。患者平均年龄为64岁。第一组有6例患者，第二组有1例患者需要导尿。因此，第一组15%的患者和第二组2.5%的患者发生了尿潴留。导尿需求的差异具有统计学意义（p = 0.04）。疝修补术技术、疝所在身体侧别、麻醉类型、手术持续时间以及术前尿路症状的严重程度对尿潴留发生率无显著影响。
围手术期使用坦索罗辛是降低腹股沟疝修补术后尿潴留风险的有效策略。
